MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis (CFMR-lung)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- University hospital of Bordeaux
-
Bordeaux, France, 33076
- University hospital of Bordeaux
-
Créteil, France, 94010
- Hopital Henri Mondor
-
Grenoble, France, 38043
- CHRU de Grenoble
-
Lille, France, 59000
- CHRU de Lille
-
Marseille, France, 13385
- Hôpital Nord
-
Marseille, France, 13385
- Hopital Universitaire de la Timone
-
Nice, France, 06200
- Fondation Lenval
-
Paris, France, 75012
- Hôpital Armand-Trousseau
-
Paris, France, 75015
- Hôpital Necker Enfant Malades
-
Tours, France, 37044
- CHRU Bretonneau-Tours
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
male or female children (age ≥ 8 y.o) and adult patient with a diagnosis of cystic fibrosis provided by genetic and swear test older than 8 years. Subgroups of patients will be defined according to:
- age: younger or older 18y.o. We expect around 50% in different subgroups. In case of, we reach 50% in one of these groups, patient recruitment will continue for both groups until the expected number of patients in the study is reached.
- brand name of magnet: Siemens, General Electric or Philips
- new drugs use: association Ivacaftor/lumicaftor (OrkambiØ) or Ivacaftor only (Kalydeco Ø) ) We expect approximately 20% to 50% of patients treated
- Informed consent provided to the patient or/and to legal representative for adults and to parents for the children
- Patient concerned by articles L 1121-6, L 1121-7, and L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent) if the expected benefit for such persons justifies the foreseeable risk incurred
Exclusion Criteria:
- patients without any social security or health insurance
- pregnant women
- Patients with previous pulmonary transplantation or planned for transplantation in the year following inclusion
- MRI contraindications:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: lung MRI
lung MRI without contrast injection
|
lung MRI without contrast injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of MRI to detect lung changes
Time Frame: Month 36
|
deterioration or improvement measured by the Helbich-Bhalla scoring with CT as gold standard
|
Month 36
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of MRI to Helbich-Bhalla scoring change
Time Frame: Month 0 and Month 36
|
Sensitivity of MRI to Helbich-Bhalla scoring change in various subgroups of patients according to age, centers and MR scan manufacturers, and new treatment drug use (Ivacaftor/lumicaftor: Orkambi Ø or Ivacaftor : Kalydeco Ø ) from CT and MR examinations
|
Month 0 and Month 36
|
|
CT / MR concordance
Time Frame: Month 0 and Month 36
|
Concordance between CT and MR in amplitude of Helbich-Bhalla scoring variations at M0 and M36
|
Month 0 and Month 36
|
|
Sensitivity of the 3D-UTE MR sequence
Time Frame: Month 0 and Month 36
|
Sensitivity of the 3D-UTE MR sequence alone to detect change in Helbich-Bhalla scoring as compared to CT performed at M0 and M36
|
Month 0 and Month 36
|
|
Imaging quality of the 3D-UTE MR
Time Frame: Month 0, Month 12, Month 24 and Month 36
|
using a likert scale
|
Month 0, Month 12, Month 24 and Month 36
|
|
Correlation between a specific Helbich-Bhalla MR score and the amplitude of change
Time Frame: Month 0 and Month 36
|
Correlation between a specific Helbich-Bhalla MR score with clinical and functional data, and concordance with the amplitude of change between M0 and M36
|
Month 0 and Month 36
|
|
Accuracy of a lung MR protocol
Time Frame: Month 0 and Month 36
|
Accuracy of a lung MR protocol including T1-weighted and T2-weighted sequences to diagnose allergic broncho-pulmonary aspergillosis (ABPA) in CF patients
|
Month 0 and Month 36
|
|
Reproducibility in detecting lung structural abnormality
Time Frame: Month 0 and Month 36
|
MR and CT reproducibility in detecting lung structural abnormality at the segmental level
|
Month 0 and Month 36
|
|
Reproducibility in overall Helbich-Bhalla scoring
Time Frame: Month 0 and Month 36
|
MR and CT reproducibility in overall Helbich-Bhalla scoring
|
Month 0 and Month 36
|
|
Correlations between Helbich-Bhalla scoring and clinical questionnaire
Time Frame: Month 0 and Month 36
|
Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical questionnaire
|
Month 0 and Month 36
|
|
Correlations between Helbich-Bhalla scoring and exacerbation rate
Time Frame: Month 0 and Month 36
|
Correlations between Helbich-Bhalla scoring measured with MRI and CT and exacerbation rate
|
Month 0 and Month 36
|
|
Correlations between Helbich-Bhalla scoring and clinical pulmonary functional test
Time Frame: Month 0 and Month 36
|
Correlations between Helbich-Bhalla scoring measured with MRI and CT and clinical pulmonary functional test
|
Month 0 and Month 36
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2016/28
- 2017-A00764-49 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.